CN1510147A - 测定α-N-乙酰氨基半乳糖苷酶活性的方法 - Google Patents

测定α-N-乙酰氨基半乳糖苷酶活性的方法 Download PDF

Info

Publication number
CN1510147A
CN1510147A CNA031480365A CN03148036A CN1510147A CN 1510147 A CN1510147 A CN 1510147A CN A031480365 A CNA031480365 A CN A031480365A CN 03148036 A CN03148036 A CN 03148036A CN 1510147 A CN1510147 A CN 1510147A
Authority
CN
China
Prior art keywords
plasma
acetylgalactosaminidase
serum
activity
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA031480365A
Other languages
English (en)
Chinese (zh)
Inventor
������ɽ����
山本信人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/478,121 external-priority patent/US5620846A/en
Application filed by Individual filed Critical Individual
Publication of CN1510147A publication Critical patent/CN1510147A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
CNA031480365A 1995-06-07 1996-06-05 测定α-N-乙酰氨基半乳糖苷酶活性的方法 Pending CN1510147A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/478,121 US5620846A (en) 1995-06-07 1995-06-07 Diagnostic and prognostic indices for cancer and aids
US08/478121 1995-06-07
US08/618485 1996-03-19
US08/618,485 US6410269B1 (en) 1995-06-07 1996-03-19 Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNB961958081A Division CN1174097C (zh) 1995-06-07 1996-06-05 由克隆的维生素d结合蛋白衍生的巨噬细胞激活因子

Publications (1)

Publication Number Publication Date
CN1510147A true CN1510147A (zh) 2004-07-07

Family

ID=27045792

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA031480365A Pending CN1510147A (zh) 1995-06-07 1996-06-05 测定α-N-乙酰氨基半乳糖苷酶活性的方法
CNB961958081A Expired - Fee Related CN1174097C (zh) 1995-06-07 1996-06-05 由克隆的维生素d结合蛋白衍生的巨噬细胞激活因子

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB961958081A Expired - Fee Related CN1174097C (zh) 1995-06-07 1996-06-05 由克隆的维生素d结合蛋白衍生的巨噬细胞激活因子

Country Status (12)

Country Link
US (3) US6410269B1 (https=)
EP (3) EP1443112A3 (https=)
JP (1) JPH11511962A (https=)
CN (2) CN1510147A (https=)
AT (1) ATE307885T1 (https=)
AU (1) AU6253596A (https=)
BR (1) BR9609072A (https=)
CA (1) CA2223940A1 (https=)
DE (2) DE69635346T4 (https=)
ES (1) ES2252756T3 (https=)
NO (1) NO323155B1 (https=)
WO (1) WO1996040903A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596223A (zh) * 2009-08-22 2012-07-18 查尔斯·肯尼萨维奇 杀肿瘤的、杀菌的、或杀病毒的巨噬细胞的激活
CN109415428A (zh) * 2016-04-21 2019-03-01 Hg制药有限公司 选择性去糖基化的维生素d结合蛋白(gcmaf)，胆钙化醇(骨化醇)和制备方法
CN118325844A (zh) * 2023-09-07 2024-07-12 武汉奥科博泰生物科技有限公司 识别N-乙酰-β-D-氨基葡萄糖苷酶的单克隆抗体及其应用

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985545A (en) * 1996-03-19 1999-11-16 Yamamoto; Nobuto Diagnostic and prognostic ELISA assays of serum α-N-acetylgalactosaminidase for AIDS
EP1280546A4 (en) * 2000-05-09 2005-02-23 Childrens Medical Center METHOD AND COMPOSITION FOR THE TREATMENT OF ANGIOGENESIS
AU2001288853A1 (en) * 2000-09-07 2002-03-22 The Brigham And Women's Hospital, Inc. Methods of detecting cancer based on prostasin
US20050009120A1 (en) * 2000-09-07 2005-01-13 The Brigham And Women's Hospital, Inc. Methods of detecting ovarian cancer based on osteopontin
CA2426154A1 (en) * 2000-11-09 2002-08-01 Northeastern Ohio Universities College Of Medicine Agents and methods for promoting bone growth
WO2002075314A2 (en) * 2000-11-30 2002-09-26 Matritech, Inc. Detection and treatment of prostate cancer
US7112408B2 (en) * 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
US7288383B2 (en) * 2003-01-15 2007-10-30 The Brigham And Women's Hospital, Inc. Eosinophil-derived neurotoxin as a marker for ovarian cancer
US8034773B2 (en) 2004-02-05 2011-10-11 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8178649B2 (en) 2004-12-07 2012-05-15 Arizona Biomedical Research Commission Immunostimulatory compositions and uses thereof
USRE46425E1 (en) 2006-12-13 2017-06-06 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US8496942B2 (en) 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
US8460697B2 (en) 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US7811995B2 (en) 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
US7838497B2 (en) 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
JP5860401B2 (ja) 2010-09-03 2016-02-16 森田薬品工業株式会社 新規Ｇｃグロブリンガラクトース脱糖体の製造方法
CN103547280B (zh) * 2011-04-07 2017-06-09 艾弗兰纳特有限公司 用于药物组合物的巨噬细胞活化因子
EP2561879A1 (en) 2011-08-23 2013-02-27 Protea Biopharma N.V. Macrophage activating factor for use in the treatment of chronic fatigue syndrome (CFS) and CFS-related diseases and disorders
EP2819749A4 (en) * 2012-03-01 2016-03-02 Univ Columbia BIOMARKERS FOR AUTISM AND USES THEREOF
EP2687264A1 (en) 2012-07-17 2014-01-22 Protea Biopharma N.V. Macrophage Activating Factor for treatment of endometriosis
AU2014207429B2 (en) * 2013-01-18 2018-11-01 Ellis KLINE Selective glycosidase regimen for immune programming and treatment of cancer
US20160120946A1 (en) * 2013-06-09 2016-05-05 Efranat Ltd. Compositions comprising gc-macrophage activating factor and uses thereof
WO2019117295A1 (ja) * 2017-12-15 2019-06-20 公益財団法人神戸医療産業都市推進機構 活性型ＧｃＭＡＦの製造方法
AU2021398261A1 (en) 2020-12-08 2023-07-06 Saisei Pharma Co., Ltd. Macrophage activator

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5326749A (en) 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
US5177001A (en) 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5516657A (en) * 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
US5652352A (en) * 1994-03-31 1997-07-29 Amgen Inc. Afamin: a human serum albumin-like gene

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596223A (zh) * 2009-08-22 2012-07-18 查尔斯·肯尼萨维奇 杀肿瘤的、杀菌的、或杀病毒的巨噬细胞的激活
CN109415428A (zh) * 2016-04-21 2019-03-01 Hg制药有限公司 选择性去糖基化的维生素d结合蛋白(gcmaf)，胆钙化醇(骨化醇)和制备方法
CN109415428B (zh) * 2016-04-21 2022-03-29 Hg制药有限公司 选择性去糖基化的维生素d结合蛋白(gcmaf)，胆钙化醇(骨化醇)和制备方法
CN118325844A (zh) * 2023-09-07 2024-07-12 武汉奥科博泰生物科技有限公司 识别N-乙酰-β-D-氨基葡萄糖苷酶的单克隆抗体及其应用

Also Published As

Publication number Publication date
WO1996040903A1 (en) 1996-12-19
US6410269B1 (en) 2002-06-25
EP1443112A3 (en) 2004-11-03
CA2223940A1 (en) 1996-12-19
DE69635346T4 (de) 2007-11-08
NO323155B1 (no) 2007-01-08
AU6253596A (en) 1996-12-30
EP1340815A2 (en) 2003-09-03
EP0837932A1 (en) 1998-04-29
ATE307885T1 (de) 2005-11-15
JPH11511962A (ja) 1999-10-19
DE69635346D1 (de) 2005-12-01
EP0837932B1 (en) 2005-10-26
EP1443112A2 (en) 2004-08-04
EP1340815A3 (en) 2003-09-17
CN1174097C (zh) 2004-11-03
CN1191567A (zh) 1998-08-26
DE69635346T2 (de) 2006-07-27
NO975771D0 (no) 1997-12-08
EP0837932A4 (en) 2001-02-28
ES2252756T3 (es) 2006-05-16
US20020055140A1 (en) 2002-05-09
US5712104A (en) 1998-01-27
BR9609072A (pt) 2000-10-24
NO975771L (no) 1998-01-30

Similar Documents

Publication Publication Date Title
CN1174097C (zh) 由克隆的维生素d结合蛋白衍生的巨噬细胞激活因子
CN1149887A (zh) 刺激和增强保护性免疫反应和il-12产生的化合物和方法
CN1322213A (zh) 炎症疾病的治疗
CN1328567A (zh) 乳房珠蛋白,一种分泌性乳房特异性乳腺癌蛋白
CN1159828A (zh) 修饰的胶原诱导血小板凝集抑制剂Pallidipin的制备方法
CN1277633A (zh) 促甲状腺激素的突变体及其制备方法
CN1150317C (zh) 一种食管癌相关新基因
JP2001231578A (ja) Ｉｌ−１ファミリーに属する蛋白質
CN1238010A (zh) 牛泌乳相关的亲免疫性蛋白(cd14),编码基因以及在b细胞激活中的应用
CN1240836C (zh) 转化生长因子αHI
RU2198218C2 (ru) СПОСОБ КЛОНИРОВАНИЯ СВЯЗЫВАЮЩЕГО ВИТАМИН D3 БЕЛКА (БЕЛКА Gc), СПОСОБ ПОЛУЧЕНИЯ КЛОНИРОВАННОГО ФАКТОРА АКТИВАЦИИ МАКРОФАГОВ, ФАКТОР АКТИВАЦИИ МАКРОФАГОВ (ВАРИАНТЫ), АДЪЮВАНТ (ВАРИАНТЫ), КЛОНИРОВАННЫЙ СВЯЗЫВАЮЩИЙ ВИТАМИН D3 БЕЛОК (Gc-БЕЛОК), КЛОНИРОВАННЫЙ ДОМЕН III СВЯЗЫВАЮЩЕГО ВИТАМИН D3 БЕЛКА (ВАРИАНТЫ)
CN1224710C (zh) 一种新的人溶菌酶基因、其编码的多肽及制备方法
US20060014143A1 (en) Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
Das et al. High-level expression of biologically active human prolactin from recombinant baculovirus in insect cells
CN1158623A (zh) 新的免疫避孕肽
CN1129666C (zh) 金属蛋白酶－4的人组织抑制剂
CN1327389A (zh) 偶联因子6抑制剂和活化剂及其用途
CN1182431A (zh) 人Criptin生长因子
CN1495258A (zh) 金属蛋白酶-4的人组织抑制剂
CN1269416A (zh) 一种新的人爱滋病毒周转蛋白异构体蛋白及其编码序列
CN1268568A (zh) 一种新的人线粒体溶质载体蛋白及其编码序列
CN101028522A (zh) MNSFβ基因在胚胎着床过程中的功能及其应用
CN1183804A (zh) 成纤维细胞生长因子15
CN1264741A (zh) 一种新的人二磷酸腺苷核糖基葡萄糖水解酶蛋白及其编码序列
CN1185159A (zh) 人血管内皮生长因子3

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CI01 Publication of corrected invention patent application

Correction item: Address

Correct: American Pennsylvania

False: The United States Binjiufaniya state

Number: 27

Volume: 20

CI02 Correction of invention patent application

Correction item: Address

Correct: American Pennsylvania

False: The United States Binjiufaniya state

Number: 27

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: PENNSILVANIA, AMERICA TO: PENNSYLVANIA, AMERICA

ERR Gazette correction

Free format text: CORRECT: ADDRESS; FROM: PENNSILVANIA, AMERICA TO: PENNSYLVANIA, AMERICA

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication